checkAd

    DGAP-News  2766  0 Kommentare Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features)


    DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel
    Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with
    additional features)

    23.07.2015 / 20:04

    ---------------------------------------------------------------------

    PRESS RELEASE N 11 / 2015 of 07/23/2015

    Dr. med. Mariola Söhngen will be the new CEO of
    MOLOGEN AG

    Berlin, July 23, 2015 - The Supervisory Board of biotechnology company
    MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive
    Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from
    November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION
    Deutschland GmbH. She will remain at PAION in her role as Chief Medical
    Officer (CMO) up to October 31, 2015, with responsibility for phase I to IV
    clinical development, regulatory and approval issues, pharmaceutical drug
    safety, quality assurance, project management, Human Resources (HR),
    Intellectual Property (IP) as well as preclinical research and development.
    In addition, Dr. Söhngen played a decisive role in the company's successful
    financing and licensing agreements.

    When she assumes the role of CEO at MOLOGEN, she will be in charge of
    Research, Business Development, Strategy and Partnering. Dr. Matthias
    Schroff will resign from his post as chairman of the Executive Board on
    October 31, 2015 and will be leaving the Executive Board with effect from
    December 31, 2015, by mutual agreement with the Supervisory Board. In the
    interim period from November 1, 2015 to December 31, 2015, Dr. Schroff
    intends to provide support as an Executive Board Member, cooperating with
    Dr. Söhngen to ensure a smooth transition of the chairmanship.

    In addition, Jörg Petraß (Chief Financial Officer; CFO) also took the
    decision in mutual agreement to not extend his contract, which is due to
    expire on December 31, 2015, and will be leaving the Executive Board.
    However, he has offered to act as a consultant for a transitional period to
    enable orderly succession planning and the induction of his successor.

    Oliver Krautscheid, Chairman of the Supervisory Board of MOLOGEN AG: "We
    are delighted that Dr. Söhngen, an extremely competent biotech and pharma
    manager, has agreed to take on the post of CEO. As co-founder of a
    successful listed German company, she has already proved her credentials as
    an entrepreneur in the biotech and pharma sector. She is a renowned biotech
    and pharma expert, who has acquired a wealth of experience in clinical
    research through to the approval of pharmaceutical products and has
    negotiated several successful in- and out-licensing deals. This means she
    is an ideal choice for the post of CEO, in order to lead MOLOGEN AG through
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features) DGAP-News: MOLOGEN AG / Key word(s): Change of Personnel Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features) 23.07.2015 / 20:04 --------------------------------------------------------------------- PRESS …